<?xml version="1.0" encoding="UTF-8"?><TED_EXPORT xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://publications.europa.eu/resource/schema/ted/R2.0.9/publication" xmlns:n2016="http://publications.europa.eu/resource/schema/ted/2016/nuts" xsi:schemaLocation="http://publications.europa.eu/resource/schema/ted/R2.0.9/publication TED_EXPORT.xsd" VERSION="R2.0.9.S03.E01" DOC_ID="339933-2019" EDITION="2019138"><TECHNICAL_SECTION><RECEPTION_ID>19-348606-001</RECEPTION_ID><DELETION_DATE>20191025</DELETION_DATE><FORM_LG_LIST>EN </FORM_LG_LIST><COMMENTS>From Convertor</COMMENTS></TECHNICAL_SECTION><LINKS_SECTION><XML_SCHEMA_DEFINITION_LINK xlink:type="simple" xlink:href="http://ted.europa.eu" xlink:title="TED WEBSITE"/><OFFICIAL_FORMS_LINK xlink:type="simple" xlink:href="http://ted.europa.eu"/><FORMS_LABELS_LINK xlink:type="simple" xlink:href="http://ted.europa.eu"/><ORIGINAL_CPV_LINK xlink:type="simple" xlink:href="http://ted.europa.eu"/><ORIGINAL_NUTS_LINK xlink:type="simple" xlink:href="http://ted.europa.eu"/></LINKS_SECTION><CODED_DATA_SECTION><REF_OJS><COLL_OJ>S</COLL_OJ><NO_OJ>138</NO_OJ><DATE_PUB>20190719</DATE_PUB></REF_OJS><NOTICE_DATA><NO_DOC_OJS>2019/S 138-339933</NO_DOC_OJS><URI_LIST><URI_DOC LG="EN">http://ted.europa.eu/udl?uri=TED:NOTICE:339933-2019:TEXT:EN:HTML</URI_DOC></URI_LIST><LG_ORIG>EN</LG_ORIG><ISO_COUNTRY VALUE="UK"/><IA_URL_GENERAL>http://www.nhsscotlandprocurement.scot.nhs.uk/</IA_URL_GENERAL><ORIGINAL_CPV CODE="33600000">Pharmaceutical products</ORIGINAL_CPV><n2016:PERFORMANCE_NUTS CODE="UKM">SCOTLAND</n2016:PERFORMANCE_NUTS><n2016:CA_CE_NUTS CODE="UKM">SCOTLAND</n2016:CA_CE_NUTS><n2016:TENDERER_NUTS CODE="UK">UNITED KINGDOM</n2016:TENDERER_NUTS><VALUES><VALUE TYPE="PROCUREMENT_TOTAL" CURRENCY="GBP">8741000</VALUE></VALUES></NOTICE_DATA><CODIF_DATA><DS_DATE_DISPATCH>20190717</DS_DATE_DISPATCH><AA_AUTHORITY_TYPE CODE="6">Body governed by public law</AA_AUTHORITY_TYPE><TD_DOCUMENT_TYPE CODE="V">Voluntary ex ante transparency notice</TD_DOCUMENT_TYPE><NC_CONTRACT_NATURE CODE="2">Supplies</NC_CONTRACT_NATURE><PR_PROC CODE="T">Negotiated without a prior call for competition</PR_PROC><RP_REGULATION CODE="5">European Union, with participation by GPA countries</RP_REGULATION><TY_TYPE_BID CODE="9">Not applicable</TY_TYPE_BID><AC_AWARD_CRIT CODE="Z">Not specified</AC_AWARD_CRIT><MA_MAIN_ACTIVITIES CODE="H">Health</MA_MAIN_ACTIVITIES><HEADING>01B15</HEADING><INITIATOR>01</INITIATOR></CODIF_DATA></CODED_DATA_SECTION><TRANSLATION_SECTION><ML_TITLES><ML_TI_DOC LG="BG"><TI_CY>Обединено кралство</TI_CY><TI_TOWN>Единбург</TI_TOWN><TI_TEXT><P>Фармацевтични продукти</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="CS"><TI_CY>Spojené království/Velká Británie</TI_CY><TI_TOWN>Edinburgh</TI_TOWN><TI_TEXT><P>Léčivé přípravky a zdravotnické prostředky</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="DA"><TI_CY>Forenede Kongerige, Det</TI_CY><TI_TOWN>Edinburgh</TI_TOWN><TI_TEXT><P>Lægemidler</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="DE"><TI_CY>das Vereinigte Königreich</TI_CY><TI_TOWN>Edinburgh</TI_TOWN><TI_TEXT><P>Arzneimittel</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="EL"><TI_CY>Ηνωμένο Βασίλειο</TI_CY><TI_TOWN>Εδιμβούργο</TI_TOWN><TI_TEXT><P>Φαρμακευτικά προϊόντα</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="EN"><TI_CY>United Kingdom</TI_CY><TI_TOWN>Edinburgh</TI_TOWN><TI_TEXT><P>Pharmaceutical products</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="ES"><TI_CY>Reino Unido</TI_CY><TI_TOWN>Edimburgo</TI_TOWN><TI_TEXT><P>Productos farmacéuticos</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="ET"><TI_CY>Suurbritannia / Ühendkuningriik</TI_CY><TI_TOWN>Edinburgh</TI_TOWN><TI_TEXT><P>Ravimid</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="FI"><TI_CY>Yhdistynyt kuningaskunta</TI_CY><TI_TOWN>Edinburgh</TI_TOWN><TI_TEXT><P>Farmaseuttiset tuotteet</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="FR"><TI_CY>Royaume-Uni</TI_CY><TI_TOWN>Édimbourg</TI_TOWN><TI_TEXT><P>Produits pharmaceutiques</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="GA"><TI_CY>Ríocht Aontaithe, an</TI_CY><TI_TOWN>Dún Éideann</TI_TOWN><TI_TEXT><P>Pharmaceutical products</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="HR"><TI_CY>Ujedinjena Kraljevina</TI_CY><TI_TOWN>Edinburgh</TI_TOWN><TI_TEXT><P>Farmaceutski proizvodi</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="HU"><TI_CY>Egyesült Királyság</TI_CY><TI_TOWN>Edinburgh</TI_TOWN><TI_TEXT><P>Gyógyszerészeti termékek</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="IT"><TI_CY>Regno Unito</TI_CY><TI_TOWN>Edimburgo</TI_TOWN><TI_TEXT><P>Prodotti farmaceutici</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="LT"><TI_CY>Jungtinė Karalystė, Didžioji Britanija</TI_CY><TI_TOWN>Edinburgas</TI_TOWN><TI_TEXT><P>Farmacijos produktai</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="LV"><TI_CY>Apvienotā Karaliste</TI_CY><TI_TOWN>Edinburga</TI_TOWN><TI_TEXT><P>Farmācijas izstrādājumi</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="MT"><TI_CY>Ir-Renju Unit</TI_CY><TI_TOWN>Edinbugh</TI_TOWN><TI_TEXT><P>Prodotti farmaċewtiċi</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="NL"><TI_CY>Verenigd Koninkrijk</TI_CY><TI_TOWN>Edinburgh</TI_TOWN><TI_TEXT><P>Farmaceutische producten</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="PL"><TI_CY>Zjednoczone Królestwo</TI_CY><TI_TOWN>Edynburg</TI_TOWN><TI_TEXT><P>Produkty farmaceutyczne</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="PT"><TI_CY>Reino Unido</TI_CY><TI_TOWN>Edimburgo</TI_TOWN><TI_TEXT><P>Produtos farmacêuticos</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="RO"><TI_CY>Regatul Unit</TI_CY><TI_TOWN>Edinburgh</TI_TOWN><TI_TEXT><P>Produse farmaceutice</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="SK"><TI_CY>Spojené kráľovstvo</TI_CY><TI_TOWN>Edinburgh</TI_TOWN><TI_TEXT><P>Farmaceutické výrobky</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="SL"><TI_CY>Združeno kraljestvo</TI_CY><TI_TOWN>Edinburgh</TI_TOWN><TI_TEXT><P>Farmacevtski proizvodi</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="SV"><TI_CY>Förenade kungariket</TI_CY><TI_TOWN>Edinburgh</TI_TOWN><TI_TEXT><P>Läkemedel</P></TI_TEXT></ML_TI_DOC></ML_TITLES><ML_AA_NAMES><AA_NAME LG="EN">The Common Services Agency (more commonly known as NHS National Services Scotland) (‘NSS’)</AA_NAME></ML_AA_NAMES></TRANSLATION_SECTION><FORM_SECTION><NOTICE_UUID>a12359a8-6689-4753-bc9a-699425138498</NOTICE_UUID><F15_2014 CATEGORY="ORIGINAL" FORM="F15" LG="EN"><LEGAL_BASIS VALUE="32014L0024"/><CONTRACTING_BODY><ADDRESS_CONTRACTING_BODY><OFFICIALNAME>The Common Services Agency (more commonly known as NHS National Services Scotland) (‘NSS’)</OFFICIALNAME><ADDRESS>Gyle Square (NSS Head Office), 1 South Gyle Crescent</ADDRESS><TOWN>Edinburgh</TOWN><POSTAL_CODE>EH12 9EB</POSTAL_CODE><COUNTRY VALUE="UK"/><CONTACT_POINT>Hazel Johnstone</CONTACT_POINT><PHONE>+44 1698794410</PHONE><E_MAIL>hazel.johnstone@nhs.net</E_MAIL><n2016:NUTS CODE="UKM"/><URL_GENERAL>http://www.nhsscotlandprocurement.scot.nhs.uk/</URL_GENERAL><URL_BUYER>https://www.publiccontractsscotland.gov.uk/search/Search_AuthProfile.aspx?ID=AA11883</URL_BUYER></ADDRESS_CONTRACTING_BODY><CA_TYPE VALUE="BODY_PUBLIC"/><CA_ACTIVITY VALUE="HEALTH"/></CONTRACTING_BODY><OBJECT_CONTRACT><TITLE><P>Supply of Myozyme®</P></TITLE><REFERENCE_NUMBER>NP92619d</REFERENCE_NUMBER><CPV_MAIN><CPV_CODE CODE="33600000"/></CPV_MAIN><TYPE_CONTRACT CTYPE="SUPPLIES"/><SHORT_DESCR><P>The supply of Alglucosidase Alfa 50mg Powder for Solution for Infusion to NHS Scotland.</P></SHORT_DESCR><VAL_TOTAL CURRENCY="GBP">8741000</VAL_TOTAL><NO_LOT_DIVISION/><OBJECT_DESCR ITEM="1"><n2016:NUTS CODE="UKM"/><MAIN_SITE><P>All entities constituted pursuant to the National Health Service (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to the new Public Bodies (Joint Working) Scotland Act 2014.</P></MAIN_SITE><SHORT_DESCR><P>The supply of Alglucosidase Alfa 50mg Powder for Solution for Infusion to NHS Scotland.</P></SHORT_DESCR><NO_OPTIONS/><NO_EU_PROGR_RELATED/></OBJECT_DESCR></OBJECT_CONTRACT><PROCEDURE><DIRECTIVE_2014_24_EU><PT_NEGOTIATED_WITHOUT_PUBLICATION><D_ACCORDANCE_ARTICLE><D_PROTECT_RIGHTS/></D_ACCORDANCE_ARTICLE><D_JUSTIFICATION><P>The medicine awarded to this framework is, and will remain to be, protected by patent for the duration of the Framework Agreement.</P></D_JUSTIFICATION></PT_NEGOTIATED_WITHOUT_PUBLICATION></DIRECTIVE_2014_24_EU><FRAMEWORK/><CONTRACT_COVERED_GPA/></PROCEDURE><AWARD_CONTRACT ITEM="1"><CONTRACT_NO>NP92619d</CONTRACT_NO><AWARDED_CONTRACT><DATE_CONCLUSION_CONTRACT>2019-06-24</DATE_CONCLUSION_CONTRACT><CONTRACTORS><NO_AWARDED_TO_GROUP/><CONTRACTOR><ADDRESS_CONTRACTOR><OFFICIALNAME>Aventis Pharma Ltd Trading As Sanofi</OFFICIALNAME><ADDRESS>One Onslow Street</ADDRESS><TOWN>Guildford</TOWN><POSTAL_CODE>GU1 4YS</POSTAL_CODE><COUNTRY VALUE="UK"/><PHONE>+44 1483554428</PHONE><n2016:NUTS CODE="UK"/></ADDRESS_CONTRACTOR><NO_SME/></CONTRACTOR></CONTRACTORS><VALUES><VAL_TOTAL CURRENCY="GBP">8741000</VAL_TOTAL></VALUES></AWARDED_CONTRACT></AWARD_CONTRACT><COMPLEMENTARY_INFO><INFO_ADD><P>The total value in Section II.1.7 and V.2.4 refers to the twenty one (21) months initial duration of the Framework Agreement and the options to extend for up to a total period of twenty seven (27) months.</P><P>For detail on the Goods awarded to this framework, please contact the named person at the head of this notice.</P><P>(SC Ref:588665)</P></INFO_ADD><ADDRESS_REVIEW_BODY><OFFICIALNAME>The Common Services Agency (more commonly known as NHS National Services Scotland) (‘NSS’)</OFFICIALNAME><ADDRESS>Gyle Square (NSS Head Office), 1 South Gyle Crescent</ADDRESS><TOWN>Edinburgh</TOWN><POSTAL_CODE>EH12 9EB</POSTAL_CODE><COUNTRY VALUE="UK"/><PHONE>+44 1698794410</PHONE><URL>http://www.nhsscotlandprocurement.scot.nhs.uk/</URL></ADDRESS_REVIEW_BODY><REVIEW_PROCEDURE><P>The notification will incorporate a ‘standstill period’ of a minimum of 10 clear calendar days (or a minimum of 15 if the communication method used is not electronic) between the date on which the Authority despatches the VEAT notice and the date on which the Authority proposes to conclude the relevant Framework Agreement. The bringing of court proceedings against the Authority during the standstill period will automatically continue the prohibition on entering into the Framework Agreement until the court proceedings are determined, discontinued or disposed of, or the court, by interim order, brings to an end the prohibition. The remedies that may be awarded by the courts before the Framework Agreement has been entered into include the setting aside of the decision to award the Framework Agreement to the winning tenderer. The bringing of court proceedings against the Authority after the Framework Agreement has been entered into will not affect the Framework Agreement unless grounds for the imposition of special penalties under the Public Contracts (Scotland) Regulations 2015 can be established. Otherwise the remedies that may be awarded by the courts where the Framework Agreement has been entered into are limited to the award of damages.</P></REVIEW_PROCEDURE><DATE_DISPATCH_NOTICE>2019-07-17</DATE_DISPATCH_NOTICE></COMPLEMENTARY_INFO></F15_2014></FORM_SECTION></TED_EXPORT>